The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.
“I’ve done a lot of work [not only with] clinical trials, but also understanding the disease, the prognostic factors, and the management of adverse effects.”
After implementing disparity and demographic reporting in acute leukemia clinical trials, investigators did not report an increase in diverse trial participants.
CancerNetwork® spoke with Jeffery Auletta, MD, about how the National Marrow Donor Program/Be The Match is using research initiatives to expand eligibility for stem cell transplants in for patient with acute leukemias and myelodysplastic syndrome.
Results of a phase 2 trial show that ibrutinib was capable of inducing responses in some patients with hairy cell leukemia who were previously treated with standard therapy options in a prior line.
SNDX-5613 has received a fast track designation from the FDA for the treatment of relapsed/refractory acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia.
Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.
A phase 2 trial evaluated the combination of vemurafenib plus rituximab, which produced a complete response in 87% of the evaluable patients with hairy-cell leukemia.
A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.
The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.